• Home
  • About
  • ‘Enforcement 40’ for 2020
  • Webcasts
  • Enforcement Hall of Fame
  • Contact
Securities Docket
Ankura 480x60
  • Class Actions
  • Criminal
  • Global
  • People
  • SD Insider
  • SEC
  • Video
  • Subscribe by email
  • Subscribe
Browse: Home / 2013 / March / 22 / Dechert Survey of Securities Fraud Class Actions Brought Against U.S. Life Sciences Companies — Dechert LLP

Dechert Survey of Securities Fraud Class Actions Brought Against U.S. Life Sciences Companies — Dechert LLP

By Securities Docket on March 22, 2013, 7:24 am

The past year was another noteworthy one with respect to securities fraud class action lawsuits against life sciences companies. There was a meaningful increase in the number of securities fraud lawsuits and a continued emphasis on industry-specific allegations of material misstatements and omissions. Although life sciences companies continue to enjoy relative success in obtaining early dismissals of these cases, the large-scale risks that follow from a securities fraud class action will only be magnified by a recent U.S. Supreme Court decision regarding class certification.

via Dechert Survey of Securities Fraud Class Actions Brought Against U.S. Life Sciences Companies — Dechert LLP

Blog Widget by LinkWithin

Posted in Class Actions | Tagged Life Sciences, Web Watch

« Previous Next »

Subscribe

‘Enforcement 40’ for 2020

Ankura 260x250

Our Sponsors

Securities-Docket_260x125_14Sec Ankura 260x125

Join Us On LinkedIn

Join the Securities Litigation and Enforcement Group on LinkedIn

Archives

Copyright © 2022 Securities Docket.

Powered by WordPress and Hybrid.